From 2D to 3D gamma passing rate tolerance and action limits for patient-specific quality assurance in volumetric-modulated arc therapy.

Abstract

Background: Volumetric modulated arc therapy (VMAT) requires an accurate patient-specific quality assurance (PSQA) program. In clinical practice, this is usually performed using the γ-index and the two-dimensional gamma passing rate (2D %GP). A three-dimensional (3D) index incorporating the patient anatomy could be more useful for the 3D dose distribution verification.

Purpose: The current study demonstrates a thorough investigation of VMAT PSQA treatment plans by examining the correlation between 3D Gamma passing rate (%GP) and 2D %GP. The aim was to establish the tolerance limits (TL) and action limits (AL) that could be adopted in clinical practice.

Materials and methods: PSQA was performed for 67 head and neck (H&N) and 69 prostate treatment plans, using an appropriate phantom and the γ-index method. The 3%/2  mm acceptance criterion was used. Treatment plans' 2D% GP and 3D %GP values were collected and correlated with individual 3D %GP values of planning target volume (PTV) and organs at risk (OARs). Institutional TL and AL of both 2D %GP and 3D %GP were established using 30 prostate and 30 H&N treatment plans, as per recommendations proposed by AAPM TG-218.

Results: A moderate correlation was observed between 2D %GP and 3D %GP of the treatment plans. Τhe correlations demonstrated a stronger association for the 3D %GP than for the 2D %GP with respect to the 3D %GP of the individual structures considered. The TL for the 3D %GP (both plan and individual) and the plans' 2D %GP were generally more stringent, while the AL showed a wider range compared to the corresponding limits suggested by the TG-218 protocol for plan 2D %GP.

Conclusions: Institution-specific 3D %GP as well as TL and AL for treatment plan, PTV and OARs could be incorporated in the PSQA procedure in synergy with the 2D evaluation, as they can provide a more-in-depth-view of the treatment quality.